Four New Alliance Trials Could Help Patients with Bladder Cancer, Breast Cancer and Advanced Neuroendocrine Tumors

The Alliance has recently activated four new trials that focus on helping patients with bladder cancer, breast cancer and neuroendocrine tumors.

Alliance A021602 - Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on everolimus

Overview: Neuroendocrine tumors (NETs) are rare neoplasms -- an abnormal growth of tissue that forms a mass. They may be benign (not cancer), or malignant (cancer), and ca


2018 Fall Group Meeting | November 1-3 Schedule  Register
2019 Spring Group Meeting | May 9-11

2019 Fall Group Meeting | November 7-9
Loews Chicago O'Hare Hotel, Rosemont, IL 60018
open to all Alliance members